TrialTransplantation and cellular therapy2022

Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma.

Meirav Kedmi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.